MAOB
ENSG00000069535
Target class
Enzyme
Chromosome
X
Approved drugs
13
Clinical candidates (approved and in development)
15
- Approved drugs
- 13
- Clinical candidates (approved and in development)
- 15
- Chemical probe available
- Yes
- Target name
- MAOB
- Gene name
- Monoamine oxidase B
- Gene symbol
- MAOB
- Protein name
- Amine oxidase [flavin-containing] B (EC 1.4.3.21) (EC 1.4.3.4) (Monoamine oxidase type B) (MAO-B)
- Gene biotype
- Protein coding
- Gene family
- Flavoproteins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 51
- Highest tissue expression
- 240.44
- Tissue specificity (Gini)
- 0.421
- Tissue specificity (tau)
- 0.76
- KEGG gene identifiers
- hsa:4129
- Reactome pathways
- R-HSA-141333
- Protein interaction confidence
- 0.899518
- Protein interaction partners
- 56
- End position
- 43882559
- Start position
- 43766400
- Chromosome
- X
- Strand
- Reverse
- Mitochondrion outer membrane
- Single-pass type IV membrane protein
- Cytoplasmic side.
- Tissue specificity (tau)
- 0.759579
- Expression inequality (Gini)
- 0.420965
Expression in transcripts per million
- Ovary
- 240.44
- Uterus
- 239.79
- Fallopian Tube
- 186.17
- Artery - Tibial
- 135.14
- Artery - Aorta
- 126.28
Expression in transcripts per million
- Ovary240.44
- Uterus239.79
- Fallopian Tube186.17
- Artery - Tibial135.14
- Artery - Aorta126.28
- Brain - Hypothalamus119.54
- Artery - Coronary103.51
- Liver99.71
- Esophagus - Gastroesophageal Junction98.37
- Brain - Nucleus accumbens (basal ganglia)95.86
- Esophagus - Muscularis90.28
- Brain - Caudate (basal ganglia)82.89
- Colon - Sigmoid77.51
- Brain - Frontal Cortex (BA9)73.14
- Adipose - Subcutaneous72.17
- Brain - Spinal cord (cervical c-1)70.48
- Breast - Mammary Tissue70.22
- Brain - Substantia nigra67.24
- Adrenal Gland64.1
- Small Intestine - Terminal Ileum62.84
- Brain - Anterior cingulate cortex (BA24)59.29
- Cervix - Endocervix59.05
- Prostate58.89
- Lung58.38
- Brain - Cortex57.34
And 29 more, listed on the interactive page.
- GO:0021762
- GO:0042420
- GO:0005739
- GO:0005740
- GO:0005741
- GO:0005515
- GO:0008131
- GO:0009055
- GO:0097621
hallucinations
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351diarrhoea
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- GI
PubMed 38773351dyskinesia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351dizziness
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351Hypertension
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CV
PubMed 38773351
Related records
Trials (144)
- 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
- A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
- A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
- A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
- A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
- A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
- A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
- A Pilot Study Assessing EmSam in Bipolar Depression
- A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
- A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
- A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
- A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers
- A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
- A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
- A Study of Decreased Mental Function Associated With HIV
- A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
- A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
- A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects
- A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics
Drugs (19)
- Iproniazid Monoamine oxidase inhibitor
- Isocarboxazid Monoamine oxidase inhibitor
- Mebanazine Monoamine oxidase inhibitor
- Nialamide Monoamine oxidase inhibitor
- Pargyline Monoamine oxidase inhibitor
- Pargyline hydrochloride Monoamine oxidase inhibitor
- Phenelzine Monoamine oxidase inhibitor
- Phenelzine sulfate Monoamine oxidase inhibitor
- Phenoxypropazine Monoamine oxidase inhibitor
- Ralfinamide Monoamine oxidase B inhibitor
- Rasagiline Monoamine oxidase B inhibitor
- Rasagiline mesylate Monoamine oxidase B inhibitor
- Rasagiline tartrate Monoamine oxidase B inhibitor
- Safinamide Monoamine oxidase B inhibitor
- Safinamide mesylate Monoamine oxidase B inhibitor
- Selegiline Monoamine oxidase B inhibitor
- Selegiline hydrochloride Monoamine oxidase B inhibitor
- Tranylcypromine Monoamine oxidase inhibitor
- Tranylcypromine sulfate Monoamine oxidase inhibitor